The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
Antimalarials
/ administration & dosage
Artemether, Lumefantrine Drug Combination
/ administration & dosage
Artemisinins
/ administration & dosage
Humans
Malaria, Vivax
/ diagnosis
Plasmodium vivax
Primaquine
/ administration & dosage
Quinolines
/ administration & dosage
Recurrence
Risk
Treatment Outcome
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
20
02
2019
accepted:
03
09
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax. Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contribute individual patient data that were pooled using standardised methodology. The effect of mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan. Secondary outcomes were the risk of recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7-49.8) compared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1-12.2): adjusted hazard ratio (AHR) 12.63 (95% CI 6.40-24.92), p < 0.001. The rates of recurrence assessed at days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for every 5-mg/kg increase 0.63 (0.48-0.84), p = 0.0013 and 0.83 (0.73-0.94), p = 0.0033, respectively. The dose of lumefantrine was not significantly associated with the rate of recurrence (1.07 for every 5-mg/kg increase, 95% CI 0.99-1.16, p = 0.0869). In a post hoc analysis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased 0.13 g/dL (95% CI 0.01-0.26) for every 5 days that recurrence was delayed, p = 0.0407. Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42 after AL (AHR = 0.20, 95% CI 0.10-0.41, p < 0.001) and at day 63 after DP (AHR = 0.08, 95% CI 0.01-0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or less and nonrandomised treatment groups. In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that delaying P. vivax recurrence was associated with a small but significant improvement in haemoglobin. These results highlight the benefits of PQ radical cure and also the provision of blood-stage antimalarial agents with prolonged post-treatment prophylaxis.
Sections du résumé
BACKGROUND
Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.
METHODS AND FINDINGS
Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42016053310. Investigators of eligible studies were invited to contribute individual patient data that were pooled using standardised methodology. The effect of mg/kg dose of piperaquine/lumefantrine, ACT administered, and PQ on the rate of P. vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan. Secondary outcomes were the risk of recurrence assessed on days 28 and 63. Nineteen studies enrolling 2,017 patients were included in the analysis. The risk of recurrent P. vivax at day 42 was significantly higher in the 384 patients treated with AL alone (44.0%, 95% confidence interval [CI] 38.7-49.8) compared with the 812 patients treated with DP alone (9.3%, 95% CI 7.1-12.2): adjusted hazard ratio (AHR) 12.63 (95% CI 6.40-24.92), p < 0.001. The rates of recurrence assessed at days 42 and 63 were associated inversely with the dose of piperaquine: AHRs (95% CI) for every 5-mg/kg increase 0.63 (0.48-0.84), p = 0.0013 and 0.83 (0.73-0.94), p = 0.0033, respectively. The dose of lumefantrine was not significantly associated with the rate of recurrence (1.07 for every 5-mg/kg increase, 95% CI 0.99-1.16, p = 0.0869). In a post hoc analysis, in patients with symptomatic recurrence after AL, the mean haemoglobin increased 0.13 g/dL (95% CI 0.01-0.26) for every 5 days that recurrence was delayed, p = 0.0407. Coadministration of PQ reduced substantially the rate of recurrence assessed at day 42 after AL (AHR = 0.20, 95% CI 0.10-0.41, p < 0.001) and at day 63 after DP (AHR = 0.08, 95% CI 0.01-0.70, p = 0.0233). Results were limited by follow-up of patients to 63 days or less and nonrandomised treatment groups.
CONCLUSIONS
In this study, we observed the risk of P. vivax recurrence at day 42 to be significantly lower following treatment with DP compared with AL, reflecting the longer period of post-treatment prophylaxis; this risk was reduced substantially by coadministration with PQ. We found that delaying P. vivax recurrence was associated with a small but significant improvement in haemoglobin. These results highlight the benefits of PQ radical cure and also the provision of blood-stage antimalarial agents with prolonged post-treatment prophylaxis.
Identifiants
pubmed: 31584960
doi: 10.1371/journal.pmed.1002928
pii: PMEDICINE-D-19-00632
pmc: PMC6777759
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Artemisinins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Primaquine
MVR3634GX1
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1002928Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200909/Z/16/Z
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI116472
Pays : United States
Organisme : Wellcome Trust
ID : 200909
Pays : United Kingdom
Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: NJW is a member of the Editorial Board of PLOS Medicine.
Références
Malar J. 2012 Aug 17;11:280
pubmed: 22900786
Am J Trop Med Hyg. 2016 Apr;94(4):879-885
pubmed: 26856909
Lancet. 2007 Mar 3;369(9563):757-765
pubmed: 17336652
Am J Trop Med Hyg. 2003 Apr;68(4):416-20
pubmed: 12875290
Malar J. 2011 Oct 11;10:297
pubmed: 21989376
Antimicrob Agents Chemother. 2005 Dec;49(12):5127-8
pubmed: 16304183
PLoS One. 2013 May 22;8(5):e63433
pubmed: 23717423
Antimicrob Agents Chemother. 2008 Mar;52(3):1040-5
pubmed: 18180357
PLoS Negl Trop Dis. 2011 Dec;5(12):e1325
pubmed: 22216359
Am J Trop Med Hyg. 2018 Mar;98(3):677-682
pubmed: 29345221
Malar J. 2017 Sep 30;16(1):392
pubmed: 28964258
PLoS Med. 2013 Dec;10(12):e1001575; discussion e1001575
pubmed: 24358031
N Engl J Med. 2008 Dec 11;359(24):2545-57
pubmed: 19064624
PLoS Med. 2013 Dec;10(12):e1001564; discussion e1001564
pubmed: 24311989
Clin Infect Dis. 2013 Feb;56(3):383-97
pubmed: 23087389
Clin Pharmacokinet. 1999 Aug;37(2):105-25
pubmed: 10496300
Malar J. 2014 Feb 28;13:73
pubmed: 24581308
Lancet Infect Dis. 2015 Jun;15(6):692-702
pubmed: 25788162
PLoS Med. 2017 Jan 10;14(1):e1002212
pubmed: 28072872
Clin Infect Dis. 2011 Nov;53(10):977-84
pubmed: 22002979
Clin Infect Dis. 2011 Mar 1;52(5):612-20
pubmed: 21292666
Lancet Infect Dis. 2010 Jun;10(6):405-16
pubmed: 20510281
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28289025
Clin Infect Dis. 2007 Apr 15;44(8):1067-74
pubmed: 17366451
PLoS Med. 2015 Jul 21;12(7):e1001855
pubmed: 26196287
BMC Med. 2015 Dec 11;13:294
pubmed: 26654101
CPT Pharmacometrics Syst Pharmacol. 2014 Aug 27;3:e132
pubmed: 25163024
Malar J. 2014 Apr 15;13:144
pubmed: 24731298
PLoS Med. 2014 Dec 30;11(12):e1001773
pubmed: 25549086
Clin Infect Dis. 2018 Jul 18;67(3):350-359
pubmed: 29873683
Antimicrob Agents Chemother. 2000 Mar;44(3):697-704
pubmed: 10681341
Lancet Infect Dis. 2018 Sep;18(9):1025-1034
pubmed: 30033231
Adv Parasitol. 2012;80:271-300
pubmed: 23199490
J Lab Clin Med. 1955 Aug;46(2):301-6
pubmed: 13242948
Trans R Soc Trop Med Hyg. 2007 Apr;101(4):351-9
pubmed: 17028048
Br J Clin Pharmacol. 2004 Mar;57(3):253-62
pubmed: 14998421
Malar J. 2018 Jan 24;17(1):45
pubmed: 29361939
Antimicrob Agents Chemother. 2012 Oct;56(10):5258-63
pubmed: 22850522
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29661873
PLoS One. 2016 Apr 29;11(4):e0154015
pubmed: 27128675
Malar J. 2012 Dec 05;11:404
pubmed: 23217037
Antimicrob Agents Chemother. 2013 Mar;57(3):1128-35
pubmed: 23254437
Malar J. 2010 Apr 21;9:105
pubmed: 20409302
Lancet Infect Dis. 2014 Oct;14(10):982-91
pubmed: 25213732
Int J Parasitol Drugs Drug Resist. 2017 Aug;7(2):181-190
pubmed: 28384505
J Infect Dis. 2013 Dec 1;208(11):1906-13
pubmed: 23926329
Clin Infect Dis. 2018 Oct 30;67(10):1543-1549
pubmed: 29889239
PLoS Med. 2017 May 16;14(5):e1002299
pubmed: 28510573
Clin Infect Dis. 2019 Apr 8;68(8):1311-1319
pubmed: 30952158